Ren Yumei, Liu Yuling, Wang Shouchuan, Lei Zhen, Yan Yongbin, Guan Xutao, Hou Jianghong, Zhu Shan, Shan Haijun, Tian Xinlei, Wang Quan, Cao Caihong, Zhang Yingying, Ma Yunfeng
Pediatric Department of The Second Clinical Medical College of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Pediatric Department of Nanjing Pukou Hospital of Chinese Medicine, Nanjing, Jiangsu 211800, P.R. China.
Exp Ther Med. 2021 Aug;22(2):899. doi: 10.3892/etm.2021.10331. Epub 2021 Jun 23.
The present study aimed to investigate the effects of zhike pingchuan granules (ZKPC) on bronchial asthma and the underlying mechanism. A bronchial asthma mouse model was established by aerosol inhalation of ovalbumin. The changes in lung pathomorphology were observed by hematoxylin and eosin staining. The levels of IL-1β, TNF-α and IL-6 in bronchoalveolar lavage fluid (BALF) and serum were detected by corresponding ELISA kits. Levels of reactive oxygen species, malondialdehyde and superoxide dismutase in lung tissues were analyzed using corresponding kits. The expression of proteins related to apoptosis and the IL-6/janus kinase 2 (JAK2)/STAT3 pathway was detected by western blot analysis. The results showed that ZKPC significantly restored the dry/wet ratio and alleviated lung pathomorphology of bronchial asthmatic mice. In addition, ZKPC inhibits inflammation, oxidative stress levels and cell apoptosis in bronchial asthmatic mice and also suppressed the IL-6/JAK2/STAT3 pathway. Fedratinib (a JAK2 inhibitor) further strengthened the alleviative effects of ZKPC on bronchial asthma. In conclusion, ZKPC improved bronchial asthma by suppressing the IL-6/JAK2/STAT3 pathway.
本研究旨在探讨止咳平喘颗粒(ZKPC)对支气管哮喘的影响及其潜在机制。通过雾化吸入卵清蛋白建立支气管哮喘小鼠模型。采用苏木精-伊红染色观察肺组织病理形态学变化。使用相应的酶联免疫吸附测定试剂盒检测支气管肺泡灌洗液(BALF)和血清中白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)的水平。使用相应试剂盒分析肺组织中活性氧、丙二醛和超氧化物歧化酶的水平。通过蛋白质印迹分析检测与细胞凋亡相关的蛋白质表达以及IL-6/Janus激酶2(JAK2)/信号转导和转录激活因子3(STAT3)信号通路。结果表明,ZKPC显著恢复了支气管哮喘小鼠的干湿比,并减轻了其肺组织病理形态学变化。此外,ZKPC抑制支气管哮喘小鼠的炎症、氧化应激水平和细胞凋亡,还抑制了IL-6/JAK2/STAT3信号通路。费德拉替尼(一种JAK2抑制剂)进一步增强了ZKPC对支气管哮喘的缓解作用。总之,ZKPC通过抑制IL-6/JAK2/STAT3信号通路改善支气管哮喘。